Monogram And Dana-Farber Cancer Institute Initiate Evaluation Of HERmark(TM) Breast C
Monogram Biosciences, Inc. (Nasdaq: MGRM) announced that it has initiated a study, in collaboration with the Dana-Farber Cancer Institute (DFCI), to evaluate Monogram's HERmark(TM) Breast Cancer Assay in metastatic breast cancer.